ABC Arbitrage SA Takes $4.99 Million Position in Takeda Pharmaceutical Co. (NYSE:TAK)

Key Points

• ABC Arbitrage SA has acquired 335,855 shares of Takeda Pharmaceutical Co. for approximately $4.99 million, making it the 28th largest holding in its investment portfolio.
• Takeda Pharmaceutical recently reported earnings per share (EPS) of $0.52, surpassing analysts' estimates of $0.47, although its revenue of $7.45 billion was below the consensus forecast of $7.96 billion.
• The company's stock has shown stability, with a current trading price of $14.27 and a market capitalization of $45.39 billion, reflecting a P/E ratio of 47.55.

ABC Arbitrage SA acquired a new stake in shares of Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 335,855 shares of the company's stock, valued at approximately $4,994,000. Takeda Pharmaceutical comprises about 0.9% of ABC Arbitrage SA's holdings, making the stock its 28th biggest holding.

A number of other institutional investors and hedge funds have also recently modified their holdings of TAK. LPL Financial LLC grew its stake in shares of Takeda Pharmaceutical by 1.9% during the fourth quarter. LPL Financial LLC now owns 186,652 shares of the company's stock valued at $2,471,000 after buying an additional 3,564 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Takeda Pharmaceutical by 94.5% during the fourth quarter. JPMorgan Chase & Co. now owns 83,826 shares of the company's stock valued at $1,110,000 after buying an additional 40,721 shares during the last quarter. Blair William & Co. IL grew its stake in shares of Takeda Pharmaceutical by 8.1% during the fourth quarter. Blair William & Co. IL now owns 12,199 shares of the company's stock valued at $162,000 after buying an additional 913 shares during the last quarter. Orion Portfolio Solutions LLC bought a new position in shares of Takeda Pharmaceutical during the fourth quarter valued at about $172,000. Finally, Franklin Resources Inc. grew its stake in shares of Takeda Pharmaceutical by 16.2% during the fourth quarter. Franklin Resources Inc. now owns 19,791 shares of the company's stock valued at $262,000 after buying an additional 2,763 shares during the last quarter. 9.17% of the stock is owned by institutional investors.

Takeda Pharmaceutical Trading Up 0.7%

Shares of NYSE:TAK traded up $0.10 on Friday, reaching $14.46. 3,045,379 shares of the company traded hands, compared to its average volume of 5,686,498. The company has a current ratio of 1.16, a quick ratio of 0.59 and a debt-to-equity ratio of 0.60. The stock has a market capitalization of $46.01 billion, a P/E ratio of 48.20 and a beta of 0.22. Takeda Pharmaceutical Co. has a 52 week low of $12.80 and a 52 week high of $15.53. The business's 50-day simple moving average is $14.82 and its 200 day simple moving average is $14.55.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its earnings results on Wednesday, July 30th. The company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.05. The company had revenue of $7.45 billion for the quarter, compared to analysts' expectations of $7.96 billion. Takeda Pharmaceutical had a return on equity of 10.50% and a net margin of 3.20%. As a group, equities analysts anticipate that Takeda Pharmaceutical Co. will post 1.64 EPS for the current fiscal year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.